Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Dose escalation phase: Primary objective: To evaluate the safety and tolerability of VIC-1911 tablets combined with osimertinib in the treatment of patients with advanced non-small cell lung cancer; Secondary objective: To determine the maximum tolerated dose (MTD) of VIC-1911 combined with osimertinib at the test dose by the incidence of dose-limiting toxicity (DLT) to provide a basis for the Phase Ib dosing; To evaluate the pharmacokinetic (PK) characteristics of VIC-1911 tablets combined with osimertinib in patients with advanced non-small cell lung cancer; To evaluate the preliminary efficacy of VIC-1911 tablets combined with osimertinib in patients with advanced non-small cell lung cancer Extension phase: Primary objective: To evaluate the safety of VIC-1911 tablets combined with osimertinib in the treatment of patients with advanced non-small cell lung cancer at the recommended dose; Secondary objective: To determine the Phase II recommended dose (RP2D) to provide a basis for subsequent clinical studies; To evaluate the PK characteristics of VIC-1911 tablets combined with osimertinib in patients with advanced non-small cell lung cancer at the recommended dose; To evaluate the preliminary efficacy of VIC-1911 tablets in combination with osimertinib at the recommended dose in patients with advanced non-small cell lung cancer.